XML 56 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Schedule of Significant Balance of Accounts Receivable The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Astellas Pharma Inc. (“Astellas”)—Related party

 

 

10

%

 

 

17

%

AstraZeneca AB (“AstraZeneca”)

 

 

26

%

 

 

81

%